[225Ac]Ac-DOTAGA.FAPi dimer / AIIMS, Johannes Gutenberg University of Mainz - LARVOL DELTA

Radiolabelled Fibroblast-Targeted Therapy in Follicular cell-derived Thyroid Cancer (ATA 2025) - "The remaining eight patients underwent tandem [¹⁷⁷Lu]Lu/[²²⁵Ac]Ac-DOTAGA.FAPi dimer therapy, consisting of a median of two cycles of [¹⁷⁷Lu]Lu-DOTAGA.FAPi dimer, followed by one cycle of [²²⁵Ac]Ac-DOTAGA.FAPi dimer, also at 8-week intervals... This study demonstrated that [¹⁷⁷Lu]Lu-DOTAGA.FAPi dimer therapy is a promising treatment option for aggressive, radioiodine-resistant thyroid cancer, with a favorable safety profile. The therapy achieved a median progression-free survival (PFS) of 29 months and a median overall survival (OS) of 32 months, with manageable adverse events. Further prospective clinical trials are required to validate these findings and compare [¹⁷⁷Lu]Lu-DOTAGA.FAPi dimer therapy with other treatment options."

Anemia • Oncology • Solid Tumor • Thrombocytopenia • Thyroid Gland Carcinoma • Thyroid Gland Follicular Carcinoma

Efficacy and Safety of [177Lu]Lu-DOTAGA.Glu(FAPi)₂ Therapy in Patients with Radioiodine-Resistant Follicular Cell-Derived Thyroid Cancers (SNMMI 2025) - "The remaining 8 patients underwent tandem [177Lu]Lu/[225Ac]Ac-DOTAGA.FAPi dimer therapy, consisting of a median of 2 cycles of [177Lu]Lu-DOTAGA.FAPi dimer followed by 1 cycle of [225Ac]Ac-DOTAGA.FAPi dimer, also at 8-week intervals... In this study, [177Lu]Lu-DOTAGA.FAPi dimer therapy showed promising safety and efficacy in aggressive, radioiodine-resistant thyroid cancer, achieving a median PFS and OS of 29 and 32 months, respectively, with manageable adverse events. Confirmation of our findings is needed from prospective clinical trials comparing [177Lu]Lu-DOTAGA.FAPi dimer therapy to other treatments."

Clinical • Anemia • Endocrine Cancer • Head and Neck Cancer • Hematological Disorders • Oncology • Solid Tumor • Thrombocytopenia • Thyroid Gland Carcinoma • Thyroid Gland Follicular Carcinoma

Long-Term Outcomes of FAPi Dimer Radionuclide Therapy in Medullary Thyroid Cancer (SNMMI 2025) - "Purpose/Background: The aim of this study is to evaluate the long-term efficacy and safety of [¹⁷⁷Lu]Lu/[225Ac]Ac-DOTAGA.FAPi dimer therapy in patients with medullary thyroid cancer (MTC)... This study demonstrates that [177Lu]Lu-DOTAGA.FAPi dimer therapy offers promising safety and efficacy in medullary thyroid cancer, with a median PFS of 26 months. However, overall survival has not yet been reached."

Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma